Long-term efficacy and safety of everolimus for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) in EXIST-1: approximately 3.5 years of exposure (P2.235)

Le résumé fourni par la source

OBJECTIVE: To examine the efficacy and safety of the oral mTOR inhibitor everolimus for the treatment of SEGA associated with TSC using data from the open-label extension phase of the EXIST-1 trial (data cutoff, January 17, 2014). BACKGROUND: TSC, an autosomal dominant genetic disorder, results in nonmalignant hamartomas in several organs. In the brain, growing SEGAs may obstruct cerebrospinal fluid flow, causing life-threatening hydrocephalus. The randomized, double-blind, phase 3 EXIST-1 trial (NCT00789828) demonstrated superiority of everolimus over placebo in reducing SEGA volume in patients with TSC. DESIGN/METHODS: Patients (median age, 9.5 years [range, 0.8-26.6 years]) received 4.5 mg/m2/day oral everolimus (n=78; titrated to target trough 5-15 ng/mL) or placebo (n=39). The primary endpoint, SEGA response rate, was defined as proportion of patients with 蠅50[percnt] reduction in sum of volumes of all target SEGA (蠅1 SEGA 蠅1 cm in longest diameter) versus baseline. Adverse events (AEs) were monitored at every visit. RESULTS: Everolimus was superior to placebo for SEGA response rate (34.6[percnt] vs 0.0[percnt]; P˂0.0001) at the original cutoff (March 2, 2011). Following these positive results, open-label everolimus was offered to all patients (including those on placebo) in an extension phase. As of January 17, 2014, 111 patients received 蠅1 dose of everolimus and were included in this extension analysis. Median duration of exposure to everolimus was 41.1 months. Best overall SEGA response rate was 53.2[percnt] (95[percnt] confidence interval [CI], 43.4-62.7[percnt]). SEGA progressions were observed in 11 (9.9[percnt]) patients. AEs were similar to previous reports. Incidences of emerging AEs decreased over time. Most frequent serious AEs reported in ˃3[percnt] of patients were pneumonia (12.6[percnt]), convulsion, (4.5[percnt]), pyrexia (4.5[percnt]), and gastroenteritis (3.6[percnt]). No significant impact on growth or sexual maturation was observed. CONCLUSIONS: Everolimus continued to show reduction in SEGA volume with no new safety concerns. Study Supported by: Novartis Pharmaceuticals Corporation

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.